[go: up one dir, main page]

ES2122958T3 - Utilizacion de una proteina bactericida/incrementando la permeabilidad o de analogos biologicamente activos de esta proteina para fabricar un medicamento para tratar las afecciones relacionadas con la endotoxina. - Google Patents

Utilizacion de una proteina bactericida/incrementando la permeabilidad o de analogos biologicamente activos de esta proteina para fabricar un medicamento para tratar las afecciones relacionadas con la endotoxina.

Info

Publication number
ES2122958T3
ES2122958T3 ES90904068T ES90904068T ES2122958T3 ES 2122958 T3 ES2122958 T3 ES 2122958T3 ES 90904068 T ES90904068 T ES 90904068T ES 90904068 T ES90904068 T ES 90904068T ES 2122958 T3 ES2122958 T3 ES 2122958T3
Authority
ES
Spain
Prior art keywords
protein
bactericide
manufacture
biologically active
related conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904068T
Other languages
English (en)
Inventor
Marian N Marra
Randal W Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2122958T3 publication Critical patent/ES2122958T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN METODO DE INHIBICION DE LIPOPOLISACARIDOS (LPS) MEDIADA POR ESTIMULACION CELULAR. ESTE METODO COMPRENDE EL CONTACTO DE CELULAS, EN LA PRESENCIA DE UNA CANTIDAD DE LIPOPOLISACARIDOS PARA LA ESTIMULACION CELULAR, CON PROTEINA AUMENTADORA DE LA PERMEABILIDAD BACTERICIDA (BPI) EN CANTIDAD SUFICIENTE PARA INHIBIR LA ESTIMULACION CELULAR.
ES90904068T 1989-02-14 1990-02-14 Utilizacion de una proteina bactericida/incrementando la permeabilidad o de analogos biologicamente activos de esta proteina para fabricar un medicamento para tratar las afecciones relacionadas con la endotoxina. Expired - Lifetime ES2122958T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31084289A 1989-02-14 1989-02-14
US07/468,696 US5089274A (en) 1989-02-14 1990-01-22 Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders

Publications (1)

Publication Number Publication Date
ES2122958T3 true ES2122958T3 (es) 1999-01-01

Family

ID=26977616

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90904068T Expired - Lifetime ES2122958T3 (es) 1989-02-14 1990-02-14 Utilizacion de una proteina bactericida/incrementando la permeabilidad o de analogos biologicamente activos de esta proteina para fabricar un medicamento para tratar las afecciones relacionadas con la endotoxina.
ES97118279T Expired - Lifetime ES2205111T3 (es) 1989-02-14 1990-02-14 Uso de una proteina bactericida/potenciadora de la permeabilidad o analogos biologicamente activos de la misma para tratar infecciones gram negativas asociadas con lipopolisacaridos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES97118279T Expired - Lifetime ES2205111T3 (es) 1989-02-14 1990-02-14 Uso de una proteina bactericida/potenciadora de la permeabilidad o analogos biologicamente activos de la misma para tratar infecciones gram negativas asociadas con lipopolisacaridos.

Country Status (11)

Country Link
US (1) US5089274A (es)
EP (3) EP0460058B1 (es)
JP (1) JP2966923B2 (es)
KR (1) KR0160133B1 (es)
AT (2) ATE169820T1 (es)
AU (1) AU647734B2 (es)
CA (1) CA2048619C (es)
DE (2) DE69032579T2 (es)
ES (2) ES2122958T3 (es)
IL (1) IL93360A (es)
WO (1) WO1990009183A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
ATE312844T1 (de) * 1987-08-11 2005-12-15 Univ New York Biologisch-aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6132775A (en) * 1987-08-11 2000-10-17 New York University Therapeutic uses of biologically active bactericidal/permeability-increasing protein fragments
US5594113A (en) 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US6093801A (en) * 1989-02-14 2000-07-25 Incyte Pharmaceuticals, Inc. Recombinant analogs of bactericidal/permeability increasing protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5171739A (en) 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
US5489676A (en) * 1990-03-30 1996-02-06 Elsbach; Peter Polypeptides that potentiate bactericidal/permeability-increasing protein and methods for treating bacterial infections
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1992009621A1 (en) * 1990-12-03 1992-06-11 New York University Biologically active bactericidal/permeability-increasing protein fragments
WO1992020715A1 (en) * 1991-05-16 1992-11-26 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
AU2872792A (en) * 1991-09-26 1993-04-27 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
EP0682524B1 (en) * 1993-02-02 2001-10-04 XOMA Technology Ltd. Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ES2157981T3 (es) * 1993-03-12 2001-09-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
JPH08511682A (ja) * 1993-04-30 1996-12-10 インサイト ファーマシューティカルズ，インク． 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
NZ275205A (en) * 1993-09-22 1998-03-25 Xoma Corp Use of bactericidal/permeability-increasing protein in treating gram-negative bacterial infection
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
CA2181165C (en) * 1994-01-14 2007-06-05 Roger G. Ii Little Anti-fungal methods and materials
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
HU221638B1 (hu) * 1994-04-21 2002-12-28 Leukotech A/S Heparinkötő fehérje alkalmazása szepszis kezelésére szolgáló gyógyszer előállítására
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US5610075A (en) * 1995-01-17 1997-03-11 Stahl-Rees; Marianne Competitive electrochemiluminescence assays for endotoxins using a ruthenium label
US5939390A (en) * 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
CA2227292A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997042966A1 (en) * 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
WO1997044354A2 (en) * 1996-05-24 1997-11-27 Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2000023101A1 (en) * 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
IL262930B2 (en) * 2016-05-27 2023-11-01 Exoxemis Inc Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006279A1 (en) * 1985-04-30 1986-11-06 Scripps Clinic And Research Foundation Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods
AU8023787A (en) * 1986-10-07 1988-05-06 Mainframe Data Ltd. Apparatus and method for controlling transmission of defects
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
ATE312844T1 (de) * 1987-08-11 2005-12-15 Univ New York Biologisch-aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
GB8815978D0 (en) * 1988-07-05 1988-08-10 British Telecomm Method & apparatus for encoding decoding & transmitting data in compressed form

Also Published As

Publication number Publication date
DE69034096T2 (de) 2004-06-17
EP0841064A1 (en) 1998-05-13
DE69032579D1 (de) 1998-09-24
JP2966923B2 (ja) 1999-10-25
EP0460058A4 (en) 1992-02-12
ATE246933T1 (de) 2003-08-15
JPH04506510A (ja) 1992-11-12
EP0460058B1 (en) 1998-08-19
AU5170690A (en) 1990-09-05
EP1384485A1 (en) 2004-01-28
ATE169820T1 (de) 1998-09-15
DE69032579T2 (de) 1999-02-11
EP0460058A1 (en) 1991-12-11
EP0841064B1 (en) 2003-08-13
IL93360A (en) 1997-04-15
DE69034096D1 (de) 2003-09-18
CA2048619C (en) 2001-02-13
ES2205111T3 (es) 2004-05-01
WO1990009183A1 (en) 1990-08-23
US5089274A (en) 1992-02-18
KR0160133B1 (en) 1998-12-01
AU647734B2 (en) 1994-03-31
CA2048619A1 (en) 1990-08-15

Similar Documents

Publication Publication Date Title
ES2122958T3 (es) Utilizacion de una proteina bactericida/incrementando la permeabilidad o de analogos biologicamente activos de esta proteina para fabricar un medicamento para tratar las afecciones relacionadas con la endotoxina.
DE69010766D1 (de) Hydrophobe Membranen.
DE69212102D1 (de) Behandlungslotion für Kontaktlinsen
DE3873112D1 (de) Abwasserbehandlungsverfahren.
BR9910671A (pt) 24-hidroxivitamina d, análogos e utilizações dos mesmos
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
DE69021435D1 (de) Ionen-Implantationsgerät.
DE69017563D1 (de) Ionenimplantationsvorrichtung.
ATE147638T1 (de) Doppeltes redoxsystem für die desinfektion von kontaktlinsen
DE69024599D1 (de) Nachfüllen von Behandlungslösung
DE3576115D1 (de) Vorrichtung zur verlagerung von gegenstaenden oder personen.
DE69017075D1 (de) Ionen-Implantationsgerät.
FR2623083B1 (fr) Prothese ligamentaire ou tendineuse et procede de fabrication de ladite prothese
ATE12159T1 (de) Desinfektions- und steril isierungszusammensetzung.
FR2645999B1 (fr) Procede de reconnaissance de la parole
DE68924743D1 (de) Digitales Konzentrationsüberwachungsgerät von Silber-Ionen für die Ausfällung von Silber-Halogen-Emulsionen.
DE3775029D1 (de) Vorrichtung zur coronaentladungsbehandlung.
IT8620970A0 (it) Eteri 5,6-epossi-7-ossabicicloeptano sostituiti utili nel trattamento di trombosi.
BR9007285A (pt) Processo para o tratamento biologico de aguas servidas com o auxilio de microorganismos
ES515833A0 (es) "perfeccionamientos en las instalaciones para la depuracion biologica de agua o aguas residuales".
FR2647249B1 (fr) Procede de reconnaissance de la parole
DE19680816D2 (de) Anlage zur Herstellung von Einlagen in Schuhe
IT1227918B (it) Impianto per la depurazione meccanico-biologica di acque di rifiuto
DE3860296D1 (de) Vorrichtung zur wasseraufbereitung.
FI885626L (fi) In-line kontaktdon.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 460058

Country of ref document: ES